MicroRNAs in diabetic nephropathy: Functions, biomarkers, and therapeutic targets

Annals of the New York Academy of Sciences

Volumn 1353, Issue 1, 2015, Pages 72-88

  Kato, Mitsuo ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Diabetic nephropathy; MicroRNAs; Noncoding RNA; Signal transduction; Therapeutics; Transforming growth factor 1

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; COLLAGEN; COLLAGEN TYPE 4; DICER; GLUCOSE; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; LOCKED NUCLEIC ACID; METHYL CPG BINDING PROTEIN 2; MICRORNA; MICRORNA 192; MICRORNA 200; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 214; MICRORNA 29A; NUCLEAR RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; PROTEIN P53; RHO KINASE; RIBONUCLEASE; RNA INDUCED SILENCING COMPLEX; RNA POLYMERASE II; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; UPSTREAM STIMULATORY FACTOR;

ALBUMINURIA; APOPTOSIS; ARTICLE; BIOGENESIS; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GLOMERULAR DYSFUNCTION; HUMAN; IN VITRO STUDY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY METASTASIS; METASTASIS POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEINURIA; RNA EDITING; RNA PROCESSING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; DIABETIC NEPHROPATHIES; GENETICS; METABOLISM; PHYSIOLOGY;

BIOMARKERS; DIABETIC NEPHROPATHIES; HUMANS; MICRORNAS;

EID: 84945444690     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12758     Document Type: Article

References (143)

1. Fineberg, D., K.A. Jandeleit-Dahm & M.E. Cooper . 2013. Diabetic nephropathy: diagnosis and treatment. Nat. Rev. Endocrinol. 9: 713-723.
2. Jones, C.A. et al. 2005. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int. 67: 1684-1691.
3. Sarnak, M.J. et al. 2003. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169.
4. de Boer, I.H. et al. 2011. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N. Engl. J. Med. 365: 2366-2376.
5. Nathan, D.M. et al. 2013. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 62: 3976-3986.
6. Colagiuri, S., C.A. Cull & R.R. Holman . 2002. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. Prospective Diabetes Study 61. Diab. Care. 25: 1410-1417.
7. Patel, A. et al. 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358: 2560-2572.
8. Decleves, A.E. & K. Sharma . 2015. Obesity and kidney disease: differential effects of obesity on adipose tissue and kidney inflammation and fibrosis. Curr. Opin. Nephrol. Hypertens. 24: 28-36.
9. The Look AHEAD Research Group. 2014. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diab. Endocrinol. 2: 801-809.
10. Chen, S., B. Jim & F.N. Ziyadeh . 2003. Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up. Semin. Nephrol. 23: 532-543.
11. Qian, Y. et al. 2008. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57: 1439-1445.
12. Kanwar, Y.S. et al. 2011. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Ann. Rev. Pathol. 6: 395-423.
13. Kato, M. & R. Natarajan . 2014. Diabetic nephropathy-emerging epigenetic mechanisms. Nat. Rev. Nephrol. 10: 517-530.
14. Pagtalunan, M.E. et al. 1997. Podocyte loss and progressive glomerular injury in type II diabetes. J. Clin. Invest. 99: 342-348.
15. Meyer, T.W., P.H. Bennett & R.G. Nelson . 1999. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 42: 1341-1344.
16. Kato, M., N.E. Castro & R. Natarajan . 2013. MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic. Biol. Med. 64: 85-94.
17. Inagi, R., Y. Ishimoto & M. Nangaku . 2014. Proteostasis in endoplasmic reticulum-new mechanisms in kidney disease. Nat. Rev. Nephrol. 10: 369-378.
18. Sharma, K. & F.N. Ziyadeh . 1995. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator. Diabetes 44: 1139-1146.
19. Yamamoto, T. et al. 1993. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 90: 1814-1818.
20. Kato, M., J.T. Park & R. Natarajan . 2012. MicroRNAs and the glomerulus. Exp. Cell Res. 318: 993-1000.
21. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
22. Ruggenenti, P., P. Cravedi & G. Remuzzi . 2010. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol. 6: 319-330.
23. Abboud, H.E. 1995. Role of platelet-derived growth factor in renal injury. Ann. Rev. Physiol. 57: 297-309.
24. Zhu, Y. et al. 2005. Role of upstream stimulatory factors in regulation of renal transforming growth factor-β1. Diabetes 54: 1976-1984.
25. Kato, M. et al. 2011. A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int. 80: 358-368.
26. Zhang, Y. et al. 1996. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 383: 168-172.
27. Roberts, A.B., B.K. McCune & M.B. Sporn . 1992. TGF-β: regulation of extracellular matrix. Kidney Int. 41: 557-559.
28. Poncelet, A.C. & H.W. Schnaper . 2001. Sp1 and Smad proteins cooperate to mediate transforming growth factor-β 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J. Biol. Chem. 276: 6983-6992.
29. Tsuchida, K. et al. 2003. Role of Smad4 on TGF-β-induced extracellular matrix stimulation in mesangial cells. Kidney Int. 63: 2000-2009.
30. Kim, Y.S. et al. 2005. Novel interactions between TGF-β1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J. Am. Soc. Nephrol. 16: 352-362.
31. Chin, B.Y. et al. 2001. Stimulation of pro-alpha(1)(I) collagen by TGF-β(1) in mesangial cells: role of the p38 MAPK pathway. Am. J. Physiol. Renal Physiol. 280: F495-504.
32. Hayashida, T. et al. 1999. TGF-β1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int. 56: 1710-1720.
33. Kato, M. et al. 2006. Role of the Akt/FoxO3a pathway in TGF-β1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J. Am. Soc. Nephrol. 17: 3325-3335.
34. Mahimainathan, L. et al. 2006. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 55: 2115-2125.
35. Bartel, D.P. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
36. Filipowicz, W., S.N. Bhattacharyya & N. Sonenberg . 2008. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9: 102-114.
37. Kim, V.N. 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. 6: 376-385.
38. Davis, B.N. et al. 2010. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell 39: 373-384.
39. Davis, B.N. et al. 2008. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56-61.
40. Suzuki, H.I. et al. 2009. Modulation of microRNA processing by p53. Nature 460: 529-533.
41. Johnson, S.M. et al. 2005. RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
42. Sampson, V.B. et al. 2007. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 67: 9762-9770.
43. Mayr, C., M.T. Hemann & D.P. Bartel . 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579.
44. Hagan, J.P., E. Piskounova & R.I. Gregory . 2009. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat. Struct. Mol. Biol. 16: 1021-1025.
45. Heo, I. et al. 2008. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol. Cell 32: 276-284.
46. Piskounova, E. et al. 2011. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147: 1066-1079.
47. Ruvkun, G. 2008. The perfect storm of tiny RNAs. Nat. Med. 14: 1041-1045.
48. Cheng, T.L. et al. 2014. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev. Cell 28: 547-560.
49. Woo, J.S. & V.N. Kim . 2014. MeCP2 caught moonlighting as a suppressor of microRNA processing. Dev. Cell 28: 477-478.
50. Bracaglia, G. et al. 2009. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep. 10: 1327-1333.
51. Jin, Y. et al. 2012. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat. Med. 18: 580-588.
52. Suzuki, H.I. et al. 2011. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol. Cell 44: 424-436.
53. Ota, H. et al. 2013. ADAR1 forms a complex with dicer to promote microRNA processing and RNA-induced gene silencing. Cell 153: 575-589.
54. Xhemalce, B., S.C. Robson & T. Kouzarides . 2012. Human RNA methyltransferase BCDIN3D regulates microRNA processing. Cell 151: 278-288.
55. Cheloufi, S. et al. 2010. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 465: 584-589.
56. Gibbings, D. et al. 2012. Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. Nat. Cell Biol. 14: 1314-1321.
57. Upton, J.P. et al. 2012. IRE1alpha cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. Science 338: 818-822.
58. Harvey, S.J. et al. 2008. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J. Am. Soc. Nephrol. 19: 2150-2158.
59. Ho, J. et al. 2008. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J. Am. Soc. Nephrol. 19: 2069-2075.
60. Ho, J. et al. 2011. The pro-apoptotic protein Bim is a microRNA target in kidney progenitors. J. Am. Soc. Nephrol. 22: 1053-1063.
61. Shi, S. et al. 2008. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am. Soc. Nephrol. 19: 2159-2169.
62. Nagalakshmi, V.K. et al. 2011. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int. 79: 317-330.
63. Zhdanova, O. et al. 2011. The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int. 80: 719-730.
64. Zhao, Y. et al. 2007. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129: 303-317.
65. Chen, J.F. et al. 2008. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. USA 105: 2111-2116.
66. Sun, Y. et al. 2004. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 32: e188.
67. Tian, Z. et al. 2008. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18: 404-411.
68. Kato, M. et al. 2007. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. USA 104: 3432-3437.
69. Kato, M. et al. 2009. TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 11: 881-889.
70. Kato, M. et al. 2010. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells. J. Biol. Chem. 285: 34004-34015.
71. Park, J.T. et al. 2013. FOG2 protein down-regulation by transforming growth factor-β1-induced microRNA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy. J. Biol. Chem. 288: 22469-22480.
72. Deshpande, S.D. et al. 2013. Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 62: 3151-3162.
73. Putta, S. et al. 2012. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 23: 458-469.
74. Kato, M. & R. Natarajan . 2012. MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy. Semin. Nephrol. 32: 253-260.
75. Kato, M. et al. 2013. TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci. Signal. 6: ra43.
76. Chung, A.C. et al. 2010. miR-192 mediates TGF-β/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 21: 1317-1325.
77. Jenkins, R.H. et al. 2012. Transforming growth factor β1 represses proximal tubular cell microRNA-192 expression through decreased hepatocyte nuclear factor DNA binding. Biochem. J. 443: 407-416.
78. Wang, Q. et al. 2008. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. Faseb J. 22: 4126-4135.
79. Wang, X.X. et al. 2010. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 59: 2916-2927.
80. Long, J. et al. 2011. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J. Biol. Chem. 286: 11837-11848.
81. Mu, J. et al. 2013. Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PloS ONE 8: e58622.
82. Sun, L. et al. 2011. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J. Pathol. 225: 364-377.
83. He, F. et al. 2014. MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia 57: 1726-1736.
84. Dey, N. et al. 2011. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J. Biol. Chem. 286: 25586-25603.
85. Zhong, X. et al. 2013. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56: 663-674.
86. Wang, J. et al. 2013. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem. Biophys. 67: 537-546.
87. Chau, B.N. et al. 2012. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Trans. Med. 4: 121ra118.
88. Zhang, Z. et al. 2009. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 583: 2009-2014.
89. Lai, J.Y. et al. 2015. MicroRNA-21 in glomerular injury. J. Am. Soc. Nephrol. 26: 805-816.
90. Li, L.-M. et al. 2011. Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product-induced apoptosis delay in monocytes. J. Immunol. 186: 2552-2560.
91. Denby, L. et al. 2014. MicroRNA-214 antagonism protects against renal fibrosis. J. Am. Soc. Nephrol. 25: 65-80.
92. Zhang, Z. et al. 2012. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Lett. 586: 20-26.
93. Wang, B. et al. 2012. Suppression of microRNA-29 Expression by TGF-β1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol. 23: 252-265.
94. Chen, H.Y. et al. 2014. MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 22: 842-853.
95. Qin, W. et al. 2011. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22: 1462-1474.
96. Du, B. et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 584: 811-816.
97. Kanasaki, K. et al. 2014. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63: 2120-2131.
98. Brennan, E.P. et al. 2013. Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. J. Am. Soc. Nephrol. 24: 627-637.
99. Wang, B. et al. 2014. Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 85: 352-361.
100. Park, J.T. et al. 2014. Repression of let-7 by transforming growth factor-β1-induced Lin28 up-regulates collagen expression in glomerular mesangial cells under diabetic conditions. Am. J. Physiol. Renal Physiol. 307: F1390-1403.
101. Li, R. et al. 2013. The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-β/Smad3-Azin1 pathway. Kidney Int. 84: 1129-1144.
102. Castro, N.E. et al. 2014. Transforming growth factor β1 (TGF-β1) enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells. J. Biol. Chem. 289: 29001-29013.
103. Wu, J. et al. 2014. Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. J. Am. Soc. Nephrol. 25: 92-104.
104. Long, J. et al. 2013. MicroRNA-22 is a master regulator of bone morphogenetic protein-7/6 homeostasis in the kidney. J. Biol. Chem. 288: 36202-36214.
105. Long, J. et al. 2010. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J. Biol. Chem. 285: 23457-23465.
106. Sedeek, M. et al. 2012. Oxidative stress, Nox isoforms and complications of diabetes-potential targets for novel therapies. J. Cardiovasc. Transl. Res. 5: 509-518.
107. Babelova, A. et al. 2012. Role of Nox4 in murine models of kidney disease. Free Radic. Biol. Med. 53: 842-853.
108. Zhu, Y., H.K. Usui & K. Sharma . 2007. Regulation of transforming growth factor β in diabetic nephropathy: implications for treatment. Semin. Nephrol. 27: 153-160.
109. Fu, Y. et al. 2010. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am. J. Nephrol. 32: 581-589.
110. Feng, B. et al. 2011. miR-146a-mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 60: 2975-2984.
111. Muratsu-Ikeda, S. et al. 2012. Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PloS ONE 7: e41462.
112. Wei, J. et al. 2014. Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgfβ1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice. Free Radical Biol. Med. 67: 91-102.
113. Krupa, A. et al. 2010. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 21: 438-447.
114. Wang, B. et al. 2010. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-β. Diabetes 59: 1794-1802.
115. Wang, B. et al. 2011. miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes 60: 280-287.
116. Gregory, P.A. et al. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10: 593-601.
117. Ren, S. & J.S. Duffield . 2013. Pericytes in kidney fibrosis. Curr. Opin. Nephrol. Hypertens. 22: 471-480.
118. LeBleu, V.S. et al. 2013. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19: 1047-1053.
119. Kriz, W., B. Kaissling & M. Le Hir . 2011. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J. Clin. Invest. 121: 468-474.
120. Breyer, M.D. et al. 2005. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16: 27-45.
121. Fassett, R.G. et al. 2011. Biomarkers in chronic kidney disease: a review. Kidney Int. 80: 806-821.
122. Farazi, T.A. et al. 2011. miRNAs in human cancer. J. Pathol. 223: 102-115.
123. Fabbri, M. 2010. miRNAs as molecular biomarkers of cancer. Expert Rev. Mol. Diagn. 10: 435-444.
124. Wang, K. et al. 2009. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. USA 106: 4402-4407.
125. Tijsen, A.J. et al. 2010. MiR423-5p as a circulating biomarker for heart failure. Circ. Res. 106: 1035-1039.
126. Szeto, C.C. et al. 2012. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Markers 33: 137-144.
127. Neal, C.S. et al. 2011. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol. Dial. Transplant. 26: 3794-3802.
128. Luk, C.C. et al. 2013. Urinary biomarkers for the prediction of reversibility in acute-on-chronic renal failure. Dis. Markers 34: 179-185.
129. Wang, G. et al. 2013. Urinary sediment miRNA levels in adult nephrotic syndrome. Clin. Chim. Acta 418: 5-11.
130. Yang, Y. et al. 2013. Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med. Hypotheses 81: 274-278.
131. Ichii, O. et al. 2012. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int. 81: 280-292.
132. DiStefano, J.K., M. Taila & M.L. Alvarez . 2013. Emerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathy. Curr. Diab. Rep. 13: 582-591.
133. Cai, X. et al. 2013. Serum microRNAs levels in primary focal segmental glomerulosclerosis. Pediatric Nephrol. (Berlin, Germany). 28: 1797-1801.
134. Huang, Y. et al. 2014. Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy: implications for glomerular endothelial injury. BMC Nephrol. 15: 142.
135. Wang, G. et al. 2012. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am. J. Nephrol. 36: 412-418.
136. Barutta, F. et al. 2013. Urinary exosomal microRNAs in incipient diabetic nephropathy. PloS ONE 8: e73798.
137. Argyropoulos, C. et al. 2013. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PloS ONE 8: e54662.
138. Ziyadeh, F.N. et al. 2000. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97: 8015-8020.
139. Decleves, A.E. & K. Sharma . 2010. New pharmacological treatments for improving renal outcomes in diabetes. Nat. Rev. Nephrol. 6: 371-380.
140. Krutzfeldt, J. et al. 2005. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
141. van Rooij, E. & S. Kauppinen . 2014. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 6: 851-864.
142. Lindow, M. & S. Kauppinen . 2012. Discovering the first microRNA-targeted drug. J. Cell Biol. 199: 407-412.
143. Pan, Y. et al. 2012. MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Intl. J. Nanomed. 7: 5957-5967.